Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> Alteration

A. Elvin, Julia; M. Gay, Laurie; Ort, Rita; Shuluk, Joseph; M. Long, Jennifer; Berger Shelley, L; Lee, Ronald; R. Chalmers, Zachary; M. Frampton, Garrett; M. Ali, Siraj; B. Schrock, Alexa; A. Miller, Vincent; J. Stephens, Philip; S. Ross, Jeffrey; C. Frank, Richard

doi:10.1634/theoncologist.2016-0310

Public

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration

Published in The Oncologist • Mar 10, 2017

Authors:

Julia A. Elvin

Laurie M. Gay

Rita Ort

Abstract

BACKGROUND: Uterine leiomyosarcoma (uLMS) responds poorly to conventional chemotherapeutic agents, and personalized therapies have yet to be systematically explored. Comprehensive genomic profiling (CGP) can identify therapeutic targets and provide insight into the biology of this highly aggressive ...

Subject

Palbociclib

CDKN2A

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!